BullFrog AI And Eleison Pharmaceuticals Enter Agreement To Collaborate To Optimize Pivotal Phase 3 Trial; Financial Terms Of The Collaboration Were Not Disclosed

Author: Benzinga Newsdesk | February 27, 2025 08:17am

BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its entry into a collaboration agreement with Eleison Pharmaceuticals Inc. ("Eleison"), a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers. Under the terms of the agreement, BullFrog AI will provide access to its BullFrog Data Networks™ AI solution to enhance clinical trial efficiency and patient insights. Financial terms of the collaboration were not disclosed.

Posted In: BFRG